MYB transcription factors are highly conserved from plants to vertebrates, indicating that
their functions embrace fundamental mechanisms in the biology of cells and organisms. In …

Proteolysis targeting chimaeras (PROTACs) is a cutting edge and rapidly growing technique
for new drug discovery and development. Currently, the largest challenge in the molecular …

Background Population-based cancer registry data from the Surveillance, Epidemiology,
and End Results (SEER) Program at the National Cancer Institute (NCI) are mainly based on …

Expression of the cell cycle regulatory gene CDK6 is required for Philadelphia-positive
(Ph+) acute lymphoblastic leukemia (ALL) cell growth, whereas expression of the closely …

Despite treatment with intensive chemotherapy, acute myelogenous leukemia (AML)
remains an aggressive malignancy with a dismal outcome in most patients. We found that …

Combining standard cytotoxic chemotherapy with BCR-ABL1 tyrosine kinase inhibitors (TKI)
has greatly improved the upfront treatment of patients with Philadelphia chromosome …

Background Melanoma, the most aggressive form of skin cancer, is characterized by high
rates of metastasis, drug resistance and mortality. Here we investigated the role of …

Identifying novel actionable factors that critically contribute to tumorigenesis is essential in
ovarian cancer, an aggressive and disseminative tumor, with limited therapeutic options …

MicroRNAs, non-coding regulators of gene expression, are likely to function as important
downstream effectors of many transcription factors including MYB. Optimal levels of MYB are …

Acute lymphoblastic leukemia (ALL) represents around 25% of adult acute leukemias.
Despite the increasing improvement in the survival rate of ALL patients during the last …